Download Oculoplastic Teaching

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Exciting Stuff!
Pathergy in Periocular Pyoderma Gangrenosum
RS Thampy,B Leatherbarrow,C Lyon
Case report
• 46 y caucasian male
• RE progressive cicatricial ectropion
7 months
Past history
• Antecedent small skin cyst upper cheek
– Treated at Walk-in Centre
Hmm not sure
what that is..
Let’s try a needle
• Fit & well
• Chemical worker
• Smokes 1x pack/day, drinks 1 bottle wine/day
Intense
dramatic
pyogenic
reaction
• Pathergy :Ulceration at site of minor trauma
• Violaceous ulceration with undermined edges
• Swabs - negative
• Biopsy: Non-specific inflammation
» Not malignant
» Not vasculitis
Empirical treatment
• Topical Fucibet
• Oral minocycline
• Reduction in inflammatory component
4 Months post-puncture
5 months later (September 09)
Progressive cribriform cicatrisation inducing further ectropion
Systemic cyclosporin with blood monitoring
Pyoderma Gangrenosum
BMJ Review Article
Brooklyn et al BMJ 2006;333:181-184
• A rare but serious neutrophilic dermatosis
• Commonly missed/ diagnosed late
• Deep ulcer with
– a well defined border,
•
•
•
•
•
usually violet or blue.
edge often undermined
surrounding skin is erythematous and indurated
Most commonly on the legs.
Patients are often systemically unwell with fever & malaise.
Lesions are usually painful and the pain can be severe.
When the lesions heal the scars are often cribriform.
Pathergy occurs in 25-50% of cases—lesions develop at the site of minor
trauma, “so surgery or debridement are
contraindicated.” ??
Subtypes
Sweet’s Syndrome
Halogenoderma
Histopathology
•
Findings:
– depend on:
• age of lesion
• site biopsied
•
Presence (or absence) of vasculitis:
– lymphocytic and/or leukocytoclastic vasculitis at advancing erythematous edge in 73% of cases)
•
Earliest lesion:
– follicular and perifollicular inflammation with intradermal abscess formation
•
Later lesions:
– necrosis of superficial dermis and epidermis:
• forms ulcer: may extend into underlying subcutis
• sometimes giant cells: particularly if associated Crohn's disease
•
Advancing edge:
– lymphocytic vasculitis:
• endothelial swelling
• disputed by some authors
– sometimes leukocytoclastic vasculitis
•
Acanthosis:
– prominent in perilesional erythematous zone
Who gets pyoderma gangrenosum?
50% are associated with underlying systemic conditions
• 30% of cases occur in patients with inflammatory bowel disease.
2% of patients with inflammatory bowel disease will develop pyoderma
PG not related to the activity of the inflammatory bowel disease, often occurs in patients whose bowel disease
is in clinical remission.
• 25% of patients have arthritis, most often seropositive rheumatoid arthritis
Activity of the arthritis is not related to pyoderma.
• Leukaemia is the most frequently reported malignancy, usually AML
PG and the eye
•
Largest series I could find : 4 pts at Moorfields
Rose et al Ophthalmology 2003
– slowly evolving, painful, unilateral blue-grey swellings of the pretarsal tissues
– progressed to frank tissue necrosis and loss of full-thickness eyelid, with patchy sparing of the lid
margin or lashes
– very distinctive preservation of the pretarsal marginal artery across full-thickness eyelid defects
– lid loss characteristically involved lateral one third of the lower eyelid (3 of 4 lids)
–
in one case, extending into the postseptal tissues in the inferotemporal orbit.
–
In 3 patients, the pyoderma, responded well to systemic immunosuppression and eyelid repair
was undertaken during the quiescent phase.
– In a single patient, relapsing disease led to loss of the eye as a result of involvement of the globe
and deep orbital tissues.
•
Other reports scleritis, PUK, orbital- coexistent with Sweet’s
Medical Treatment
• Topical steroid
• Local injection of triamcinolone under ulcer edge
• Topical tacrolimus
• Minocycline 100 mg twice daily
• Prednisolone “is the drug of choice” and is usually started at (60-120 mg)
– (level B evidence)
• IV MePred 1g pulses x 3-5
•
Cyclosporine 3-5 mg/kg
•
serious side effects, including nephrotoxicity, hypertension, and increased risk of cancer have
not been reported for the low doses used to treat pyoderma
• Infliximab + azathioprine
Procianoy et al
Arq Bras Oftalmol. 2009;72(3):384-6
Surgical Management
• Essentially shortage of anterior lamella
• Lateral tarsal strip procedure and scar tissue release with fullthickness skin grafting
• Pretreated with corticosteroid for several months
• Disease was considered quiescent for the previous 6 months under
treatment.
• Prednisolone dose increased from 40 mg/day to 60 mg/day 1 week
before surgery.
• This dose was maintained during the first month post-operatively
and tapered.
A) Preoperative B) 6-month post-operative C) Hypertrophic donor site
A
C
B
Adjacent pustular ulcerated skin over zygoma
Conclusion
• Pyoderma gangrenosum CAN be co-managed
surgically
• Excluding other diagnoses and investigation
underlying associations is essential
• Immunomodulation by experienced dermatologist is
the key to minimisinng surgical excitement
References:
1. Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad
Dermatol. 2010;62(4):646-54.
2. Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol
Venereol 2009;23(9):1008-17.
3.
Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33(4):787-802.
4. Lindberg-Larsen R, Fogh K. Traumatic pyoderma gangrenosum of the face: pathergy development after bike
accident. Dermatology 2009;218(3):272-4.
5.
Gulyas K, Kimble FW. Atypical pyoderma gangrenosum after breast reduction. Aesthetic Plast Surg 2003;27:328-331.
6. Rand RP, Olerud JE, Verrier ED. Pyoderma gangrenosum after coronary artery bypass grafting. Ann Thorac Surg
1993;55:1016-1018.
7. Banga F, Schuitemaker N, Meijer P. Pyoderma gangrenosum after caesarean section: a case report. Reprod Health
2006;3:9.
8.
Akhras V, Sarkany R, Walsh S, et al. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin
Exp Dermatol. 2009;34(5):e183-5.
9. Procianoy F, Barbato MT , Osowski LE et al. Cicatricial ectropion correction in a patient with pyoderma
gangrenosum: case report. Arq Bras Oftalmol. 2009 72(3):384-6